Needham analyst Mike Matson reiterated the Buy rating on Merit Medical Systems, Inc. (NASDAQ: MMSI), lowering the price target to $81 from $96.
Merit Medical delivered a street-beating performance in Q3 2023, where reported revenue of $315.2 million was up 9.8% year-over-year.
According to the analyst, Merit Medical is undergoing a turnaround after encountering challenges with several acquisitions and seeing its operating margin decline.
Matson projects the revenue growth to return to the mid-single digits or better andFull story available on Benzinga.com